HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon

Table 3 Prevalence of HIV-1 drug resistance among CRF02_AG

Resistance Category	No. sequences	Percentage with DRM	1 DRM	2 DRMs	3 DRMs	≥4 DRMs
PI/r	64	1.6%	1	0	0	0
NRTI	64	87.5%	10	12	12	22
NNRTI	64	92.2%	33	20	6	0

Legend. PI/r ritonavir boosted protease inhibitor, NRTI nucleos(t) ide reverse transcriptase inhibitor; NNRTI non-nucleoside reverse transcriptase inhibitor, DRM drug resistance mutations

ISSN: 1471-2334